Gregory Sketas, MD
Family Medicine · Hot Springs, ARNPI 1710340088
Payments from drug & device makers
Across 269 payments — averaging $14.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Axsome Therapeutics, Inc.$260
- Pfizer$226
- GSK$202
- AstraZeneca$201
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$187
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,75699%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 132 | $1,228 |
| Axsome Therapeutics, Inc. | 10 | $260 |
| Pfizer | 14 | $226 |
| GSK | 14 | $202 |
| AstraZeneca | 11 | $201 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $187 |
| Lilly USA, LLC | 10 | $156 |
| Johnson & Johnson | 2 | $143 |
| Novo Nordisk | 9 | $138 |
| Lundbeck LLC | 7 | $127 |
| Otsuka America Pharmaceutical, Inc. | 8 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $109 |
| Hologic Sales And Service, LLC | 1 | $99 |
| Amgen(2 entities) | 4 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $72 |
| Exact Sciences | 3 | $54 |
| Dexcom, Inc. | 3 | $50 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Astellas Pharma US Inc | 1 | $28 |
| Boston Scientific | 1 | $28 |
| Novartis | 2 | $27 |
| Merck | 2 | $25 |
| Alkermes, Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $15 |
| Medtronic | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Inogen, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$125
How this compares
$3,796 in reported general payments places this provider in the 80th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $84,037 |
| VraylarCariprazine Hcl | 36 | $51,384 |
| FarxigaDapagliflozin Propanediol | 66 | $49,850 |
| MounjaroTirzepatide | 45 | $47,487 |
| EliquisApixaban | 84 | $47,278 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $39,258 |
| Abilify MaintenaAripiprazole | 12 | $34,117 |
| JardianceEmpagliflozin | 33 | $27,456 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $23,338 |
| SpravatoEsketamine Hcl | 15 | $21,868 |
| LinzessLinaclotide | 32 | $18,618 |
| CaplytaLumateperone Tosylate | 11 | $17,443 |
| RexultiBrexpiprazole | 12 | $14,598 |
| TrulicityDulaglutide | 14 | $13,611 |
| QuliptaAtogepant | 13 | $13,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $138 | $84,03779 claims |
| AbbVieVraylar, Linzess, Qulipta | $1,228 | $83,35881 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $201 | $73,18894 claims |
| Lilly USA, LLCMounjaro, Trulicity | $156 | $61,09859 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $123 | $48,71524 claims |
| PfizerEliquis | $226 | $47,27884 claims |
| GSKTrelegy Ellipta | $202 | $39,25863 claims |
| Johnson & JohnsonSpravato, Xarelto | $143 | $28,34531 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $72 | $17,44311 claims |
| MerckJanuvia | $25 | $9,50317 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $109 | $4,08611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Hot Springs
- Jodi SansonHot Springs$1.7M
- Kevin HaleHot Springs$37K
- Anna ParchmanHot Springs$28K
- Hunter CarringtonHot Springs$21K
- Scott AndersonHot Springs$15K
- Robert ParrottHot Springs$15K
- John ErwinHot Springs$12K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.